Trial Profile
A Randomized, Double-blind Placebo Controlled, open-label active controlled, single-escalation dose study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 After Single Intravenous Administration in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Efepoetin alfa (Primary) ; Darbepoetin alfa
- Indications Anaemia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 12 May 2016 New trial record